Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 8/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5547696 | 0.87 | CACNA2D1 (0.65) | CACNA2D1CACNA1BCACNB1CACNA1CMEN1 | |
| SCHEMBL5017470 | 0.81 | CACNA2D1 (0.77) | CACNA2D1CACNA1BCACNB1CACNA1CCCR2 | |
| SCHEMBL5547625 | 0.80 | CACNA2D1 (0.52) | CACNA2D1CACNA1BCACNB1CACNA1CCCR2 | |
| SCHEMBL1944375 | 0.77 | CCR2 (0.76) | CCR2KCNH2KDM4E | |
| SCHEMBL27692840 | 0.76 | CCR2 (0.53) | CACNA2D1CACNA1BCACNB1CACNA1CCCR2 | |
| SCHEMBL3394465 | 0.74 | HTT (0.60) | CACNA2D1CACNA1BCACNB1CACNA1CCCR2 | |
| SCHEMBL14270044 | 0.73 | CCR2 (0.53) | CCR2KCNH2GFER | |
| SCHEMBL2947770 | 0.72 | MC4R (0.58) | CCR2KCNH2ALDH1A1LMNA | |
| SCHEMBL2947772 | 0.72 | MC4R (0.58) | CCR2KCNH2ALDH1A1LMNA | |
| SCHEMBL1943495 | 0.71 | CCR2 (0.66) | CCR2KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | claimed |
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | ORAI1, CACNA1D, CACNA1C | CACNA2D1 51/4885CACNA1B 4/4885CACNB1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.